Bullfrog AI (NASDAQ:BFRG – Get Free Report) and Bio-Techne (NASDAQ:TECH – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Profitability
This table compares Bullfrog AI and Bio-Techne’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bullfrog AI | N/A | -217.80% | -174.57% |
| Bio-Techne | 9.05% | 13.57% | 10.66% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Bullfrog AI and Bio-Techne, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bullfrog AI | 1 | 1 | 0 | 0 | 1.50 |
| Bio-Techne | 1 | 13 | 3 | 0 | 2.12 |
Valuation & Earnings
This table compares Bullfrog AI and Bio-Techne”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bullfrog AI | $120,000.00 | 85.75 | -$6.50 million | ($0.54) | -1.03 |
| Bio-Techne | $1.22 billion | 9.25 | $73.40 million | $0.69 | 104.48 |
Bio-Techne has higher revenue and earnings than Bullfrog AI. Bullfrog AI is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Bullfrog AI has a beta of -2.8, suggesting that its stock price is 380% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Institutional & Insider Ownership
1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Bio-Techne beats Bullfrog AI on 12 of the 14 factors compared between the two stocks.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Bullfrog AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bullfrog AI and related companies with MarketBeat.com's FREE daily email newsletter.
